Bailey.Glen

User:Bailey.Glen (view source)

Revision as of 12:19, 26 January 2024

81 bytes added , 26 January

no edit summary

Line 20: Line 20:

|

−

|-|[[BRST5:Columnar_cell_lesions,_including_flat_epithelial_atypia_|Columnar cell lesions, including flat epithelial atypia ]]

+

|-

+

|[[BRST5:Columnar_cell_lesions,_including_flat_epithelial_atypia_|Columnar cell lesions, including flat epithelial atypia ]]

|Disease

|

Line 30: Line 31:

|

−

|-|[[BRST5:Atypical_ductal_hyperplasia|Atypical ductal hyperplasia]]

+

|-

+

|[[BRST5:Atypical_ductal_hyperplasia|Atypical ductal hyperplasia]]

|Disease

|

Line 40: Line 42:

|

−

|-|[[BRST5:Sclerosing_adenosis|Sclerosing adenosis]]

+

|-

+

|[[BRST5:Sclerosing_adenosis|Sclerosing adenosis]]

|Disease

|

Line 50: Line 53:

|

−

|-|[[BRST5:Apocrine_adenosis_and_adenoma|Apocrine adenosis and adenoma]]

+

|-

+

|[[BRST5:Apocrine_adenosis_and_adenoma|Apocrine adenosis and adenoma]]

|Disease

|

Line 60: Line 64:

|

−

|-|[[BRST5:Microglandular_adenosis_|Microglandular adenosis ]]

+

|-

+

|[[BRST5:Microglandular_adenosis_|Microglandular adenosis ]]

|Disease

|

Line 70: Line 75:

|

−

|-|[[BRST5:Radial_scar_/_complex_sclerosing_lesion_|Radial scar / complex sclerosing lesion ]]

+

|-

+

|[[BRST5:Radial_scar_/_complex_sclerosing_lesion_|Radial scar / complex sclerosing lesion ]]

|Disease

|

Line 80: Line 86:

|

−

|-|[[BRST5:Tubular_adenoma_|Tubular adenoma ]]

+

|-

+

|[[BRST5:Tubular_adenoma_|Tubular adenoma ]]

|Disease

|

Line 90: Line 97:

|

−

|-|[[BRST5:Lactating_adenoma_|Lactating adenoma ]]

+

|-

+

|[[BRST5:Lactating_adenoma_|Lactating adenoma ]]

|Disease

|

Line 100: Line 108:

|

−

|-|[[BRST5:Ductal_adenoma|Ductal adenoma]]

+

|-

+

|[[BRST5:Ductal_adenoma|Ductal adenoma]]

|Disease

|

Line 110: Line 119:

|

−

|-|[[BRST5:Pleomorphic_adenoma|Pleomorphic adenoma]]

+

|-

+

|[[BRST5:Pleomorphic_adenoma|Pleomorphic adenoma]]

|Disease

|

Line 120: Line 130:

|

−

|-|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]

+

|-

+

|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]

|Disease

|

Line 130: Line 141:

|

−

|-|[[BRST5:Malignant_adenomyoepithelioma|Malignant adenomyoepithelioma]]

+

|-

+

|[[BRST5:Malignant_adenomyoepithelioma|Malignant adenomyoepithelioma]]

|Disease

|

Line 140: Line 152:

|

−

|-|[[BRST5:Intraductal_papilloma|Intraductal papilloma]]

+

|-

+

|[[BRST5:Intraductal_papilloma|Intraductal papilloma]]

|Disease

|

Line 150: Line 163:

|

−

|-|[[BRST5:Papillary_ductal_carcinoma_in_situ|Papillary ductal carcinoma in situ]]

+

|-

+

|[[BRST5:Papillary_ductal_carcinoma_in_situ|Papillary ductal carcinoma in situ]]

|Disease

|

Line 160: Line 174:

|

−

|-|[[BRST5:Encapsulated_papillary_carcinoma|Encapsulated papillary carcinoma]]

+

|-

+

|[[BRST5:Encapsulated_papillary_carcinoma|Encapsulated papillary carcinoma]]

|Disease

|

Line 170: Line 185:

|

−

|-|[[BRST5:Solid_papillary_carcinoma_(in_situ_and_invasive)|Solid papillary carcinoma (in situ and invasive)]]

+

|-

+

|[[BRST5:Solid_papillary_carcinoma_(in_situ_and_invasive)|Solid papillary carcinoma (in situ and invasive)]]

|Disease

|

Line 180: Line 196:

|

−

|-|[[BRST5:Invasive_papillary_carcinoma|Invasive papillary carcinoma]]

+

|-

+

|[[BRST5:Invasive_papillary_carcinoma|Invasive papillary carcinoma]]

|Disease

|

Line 190: Line 207:

|

−

|-|[[BRST5:Atypical_lobular_hyperplasia_|Atypical lobular hyperplasia ]]

+

|-

+

|[[BRST5:Atypical_lobular_hyperplasia_|Atypical lobular hyperplasia ]]

|Disease

|

Line 200: Line 218:

|

−

|-|[[BRST5:Lobular_carcinoma_in_situ|Lobular carcinoma in situ]]

+

|-

+

|[[BRST5:Lobular_carcinoma_in_situ|Lobular carcinoma in situ]]

|Disease

|

Line 210: Line 229:

|

−

|-|[[BRST5:Ductal_carcinoma_in_situ_|Ductal carcinoma in situ ]]

+

|-

+

|[[BRST5:Ductal_carcinoma_in_situ_|Ductal carcinoma in situ ]]

|Disease

|

Line 220: Line 240:

|

−

|-|[[BRST5:Invasive_breast_carcinoma:_General_overview|Invasive breast carcinoma: General overview]]

+

|-

+

|[[BRST5:Invasive_breast_carcinoma:_General_overview|Invasive breast carcinoma: General overview]]

|Disease

|

Line 230: Line 251:

|

−

|-|[[BRST5:Invasive_breast_carcinoma_of_no_special_type|Invasive breast carcinoma of no special type]]

+

|-

+

|[[BRST5:Invasive_breast_carcinoma_of_no_special_type|Invasive breast carcinoma of no special type]]

|Disease

|

Line 240: Line 262:

|

−

|-|[[BRST5:Microinvasive_carcinoma|Microinvasive carcinoma]]

+

|-

+

|[[BRST5:Microinvasive_carcinoma|Microinvasive carcinoma]]

|Disease

|

Line 250: Line 273:

|

−

|-|[[BRST5:Invasive_lobular_carcinoma_|Invasive lobular carcinoma ]]

+

|-

+

|[[BRST5:Invasive_lobular_carcinoma_|Invasive lobular carcinoma ]]

|Disease

|

Line 260: Line 284:

|

−

|-|[[BRST5:Tubular_carcinoma|Tubular carcinoma]]

+

|-

+

|[[BRST5:Tubular_carcinoma|Tubular carcinoma]]

|Disease

|

Line 270: Line 295:

|

−

|-|[[BRST5:Cribriform_carcinoma|Cribriform carcinoma]]

+

|-

+

|[[BRST5:Cribriform_carcinoma|Cribriform carcinoma]]

|Disease

|

Line 280: Line 306:

|

−

|-|[[BRST5:Mucinous_carcinoma|Mucinous carcinoma]]

+

|-

+

|[[BRST5:Mucinous_carcinoma|Mucinous carcinoma]]

|Disease

|

Line 290: Line 317:

|

−

|-|[[BRST5:Mucinous_cystadenocarcinoma|Mucinous cystadenocarcinoma]]

+

|-

+

|[[BRST5:Mucinous_cystadenocarcinoma|Mucinous cystadenocarcinoma]]

|Disease

|

Line 300: Line 328:

|

−

|-|[[BRST5:Invasive_micropapillary_carcinoma|Invasive micropapillary carcinoma]]

+

|-

+

|[[BRST5:Invasive_micropapillary_carcinoma|Invasive micropapillary carcinoma]]

|Disease

|

Line 310: Line 339:

|

−

|-|[[BRST5:Carcinoma_with_apocrine_differentiation|Carcinoma with apocrine differentiation]]

+

|-

+

|[[BRST5:Carcinoma_with_apocrine_differentiation|Carcinoma with apocrine differentiation]]

|Disease

|

Line 320: Line 350:

|

−

|-|[[BRST5:Metaplastic_carcinoma|Metaplastic carcinoma]]

+

|-

+

|[[BRST5:Metaplastic_carcinoma|Metaplastic carcinoma]]

|Disease

|

Line 330: Line 361:

|

−

|-|[[BRST5:Acinic_cell_carcinoma|Acinic cell carcinoma]]

+

|-

+

|[[BRST5:Acinic_cell_carcinoma|Acinic cell carcinoma]]

|Disease

|

Line 340: Line 372:

|

−

|-|[[BRST5:Adenoid_cystic_carcinoma|Adenoid cystic carcinoma]]

+

|-

+

|[[BRST5:Adenoid_cystic_carcinoma|Adenoid cystic carcinoma]]

|Disease

|

Line 350: Line 383:

|

−

|-|[[BRST5:Secretory_carcinoma_|Secretory carcinoma ]]

+

|-

+

|[[BRST5:Secretory_carcinoma_|Secretory carcinoma ]]

|Disease

|

Line 360: Line 394:

|

−

|-|[[BRST5:Mucoepidermoid_carcinoma|Mucoepidermoid carcinoma]]

+

|-

+

|[[BRST5:Mucoepidermoid_carcinoma|Mucoepidermoid carcinoma]]

|Disease

|

Line 370: Line 405:

|

−

|-|[[BRST5:Polymorphous_adenocarcinoma|Polymorphous adenocarcinoma]]

+

|-

+

|[[BRST5:Polymorphous_adenocarcinoma|Polymorphous adenocarcinoma]]

|Disease

|

Line 380: Line 416:

|

−

|-|[[BRST5:Tall_cell_carcinoma_with_reversed_polarity|Tall cell carcinoma with reversed polarity]]

+

|-

+

|[[BRST5:Tall_cell_carcinoma_with_reversed_polarity|Tall cell carcinoma with reversed polarity]]

|Disease

|

Line 390: Line 427:

|

−

|-|[[BRST5:Neuroendocrine_tumour|Neuroendocrine tumour]]

+

|-

+

|[[BRST5:Neuroendocrine_tumour|Neuroendocrine tumour]]

|Disease

|

Line 400: Line 438:

|

−

|-|[[BRST5:Neuroendocrine_carcinoma|Neuroendocrine carcinoma]]

+

|-

+

|[[BRST5:Neuroendocrine_carcinoma|Neuroendocrine carcinoma]]

|Disease

|

Line 410: Line 449:

|

−

|-|[[BRST5:Hamartoma_|Hamartoma ]]

+

|-

+

|[[BRST5:Hamartoma_|Hamartoma ]]

|Disease

|

Line 420: Line 460:

|

−

|-|[[BRST5:Fibroadenoma_|Fibroadenoma ]]

+

|-

+

|[[BRST5:Fibroadenoma_|Fibroadenoma ]]

|Disease

|

Line 430: Line 471:

|

−

|-|[[BRST5:Phyllodes_tumour_|Phyllodes tumour ]]

+

|-

+

|[[BRST5:Phyllodes_tumour_|Phyllodes tumour ]]

|Disease

|

Line 440: Line 482:

|

−

|-|[[BRST5:Syringomatous_tumour_|Syringomatous tumour ]]

+

|-

+

|[[BRST5:Syringomatous_tumour_|Syringomatous tumour ]]

|Disease

|

Line 450: Line 493:

|

−

|-|[[BRST5:Nipple_adenoma_|Nipple adenoma ]]

+

|-

+

|[[BRST5:Nipple_adenoma_|Nipple adenoma ]]

|Disease

|

Line 460: Line 504:

|

−

|-|[[BRST5:Paget_disease_of_the_breast|Paget disease of the breast]]

+

|-

+

|[[BRST5:Paget_disease_of_the_breast|Paget disease of the breast]]

|Disease

|

Line 470: Line 515:

|

−

|-|[[BRST5:Haemangioma|Haemangioma]]

+

|-

+

|[[BRST5:Haemangioma|Haemangioma]]

|Disease

|

Line 480: Line 526:

|

−

|-|[[BRST5:Angiomatosis|Angiomatosis]]

+

|-

+

|[[BRST5:Angiomatosis|Angiomatosis]]

|Disease

|

Line 490: Line 537:

|

−

|-|[[BRST5:Atypical_vascular_lesions_|Atypical vascular lesions ]]

+

|-

+

|[[BRST5:Atypical_vascular_lesions_|Atypical vascular lesions ]]

|Disease

|

Line 500: Line 548:

|

−

|-|[[BRST5:Postradiation_angiosarcoma_of_the_breast|Postradiation angiosarcoma of the breast]]

+

|-

+

|[[BRST5:Postradiation_angiosarcoma_of_the_breast|Postradiation angiosarcoma of the breast]]

|Disease

|

Line 510: Line 559:

|

−

|-|[[BRST5:Primary_angiosarcoma_of_the_breast|Primary angiosarcoma of the breast]]

+

|-

+

|[[BRST5:Primary_angiosarcoma_of_the_breast|Primary angiosarcoma of the breast]]

|Disease

|

Line 520: Line 570:

|

−

|-|[[BRST5:Nodular_fasciitis|Nodular fasciitis]]

+

|-

+

|[[BRST5:Nodular_fasciitis|Nodular fasciitis]]

|Disease

|

Line 530: Line 581:

|

−

|-|[[BRST5:Myofibroblastoma|Myofibroblastoma]]

+

|-

+

|[[BRST5:Myofibroblastoma|Myofibroblastoma]]

|Disease

|

Line 540: Line 592:

|

−

|-|[[BRST5:Desmoid_fibromatosis_|Desmoid fibromatosis ]]

+

|-

+

|[[BRST5:Desmoid_fibromatosis_|Desmoid fibromatosis ]]

|Disease

|

Line 550: Line 603:

|

−

|-|[[BRST5:Inflammatory_myofibroblastic_tumour_|Inflammatory myofibroblastic tumour ]]

+

|-

+

|[[BRST5:Inflammatory_myofibroblastic_tumour_|Inflammatory myofibroblastic tumour ]]

|Disease

|

Line 560: Line 614:

|

−

|-|[[BRST5:Schwannoma_|Schwannoma ]]

+

|-

+

|[[BRST5:Schwannoma_|Schwannoma ]]

|Disease

|

Line 570: Line 625:

|

−

|-|[[BRST5:Neurofibroma_|Neurofibroma ]]

+

|-

+

|[[BRST5:Neurofibroma_|Neurofibroma ]]

|Disease

|

Line 580: Line 636:

|

−

|-|[[BRST5:Granular_cell_tumour|Granular cell tumour]]

+

|-

+

|[[BRST5:Granular_cell_tumour|Granular cell tumour]]

|Disease

|

Line 590: Line 647:

|

−

|-|[[BRST5:Leiomyoma|Leiomyoma]]

+

|-

+

|[[BRST5:Leiomyoma|Leiomyoma]]

|Disease

|

Line 600: Line 658:

|

−

|-|[[BRST5:Leiomyosarcoma_|Leiomyosarcoma ]]

+

|-

+

|[[BRST5:Leiomyosarcoma_|Leiomyosarcoma ]]

|Disease

|

Line 610: Line 669:

|

−

|-|[[BRST5:Lipoma_|Lipoma ]]

+

|-

+

|[[BRST5:Lipoma_|Lipoma ]]

|Disease

|

Line 620: Line 680:

|

−

|-|[[BRST5:Angiolipoma_|Angiolipoma ]]

+

|-

+

|[[BRST5:Angiolipoma_|Angiolipoma ]]

|Disease

|

Line 630: Line 691:

|

−

|-|[[BRST5:Liposarcoma_|Liposarcoma ]]

+

|-

+

|[[BRST5:Liposarcoma_|Liposarcoma ]]

|Disease

|

Line 640: Line 702:

|

−

|-|[[BRST5:Pseudoangiomatous_stromal_hyperplasia|Pseudoangiomatous stromal hyperplasia]]

+

|-

+

|[[BRST5:Pseudoangiomatous_stromal_hyperplasia|Pseudoangiomatous stromal hyperplasia]]

|Disease

|

Line 650: Line 713:

|

−

|-|[[BRST5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue_(MALT_lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]

+

|-

+

|[[BRST5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue_(MALT_lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]

|Disease

|

Line 660: Line 724:

|

−

|-|[[BRST5:Follicular_lymphoma_|Follicular lymphoma ]]

+

|-

+

|[[BRST5:Follicular_lymphoma_|Follicular lymphoma ]]

|Disease

|

Line 670: Line 735:

|

−

|-|[[BRST5:Diffuse_large_B-cell_lymphoma_|Diffuse large B-cell lymphoma ]]

+

|-

+

|[[BRST5:Diffuse_large_B-cell_lymphoma_|Diffuse large B-cell lymphoma ]]

|Disease

|

Line 680: Line 746:

|

−

|-|[[BRST5:Burkitt_lymphoma|Burkitt lymphoma]]

+

|-

+

|[[BRST5:Burkitt_lymphoma|Burkitt lymphoma]]

|Disease

|

Line 690: Line 757:

|

−

|-|[[BRST5:Breast_implant-associated_anaplastic_large_cell_lymphoma_|Breast implant-associated anaplastic large cell lymphoma ]]

+

|-

+

|[[BRST5:Breast_implant-associated_anaplastic_large_cell_lymphoma_|Breast implant-associated anaplastic large cell lymphoma ]]

|Disease

|

Line 700: Line 768:

|

−

|-|[[BRST5:Gynaecomastia|Gynaecomastia]]

+

|-

+

|[[BRST5:Gynaecomastia|Gynaecomastia]]

|Disease

|

Line 710: Line 779:

|

−

|-|[[BRST5:Carcinoma_in_situ|Carcinoma in situ]]

+

|-

+

|[[BRST5:Carcinoma_in_situ|Carcinoma in situ]]

|Disease

|

Line 720: Line 790:

|

−

|-|[[BRST5:Invasive_carcinoma|Invasive carcinoma]]

+

|-

+

|[[BRST5:Invasive_carcinoma|Invasive carcinoma]]

|Disease

|

Line 730: Line 801:

|

−

|-|[[BRST5:Metastases_to_the_breast|Metastases to the breast]]

+

|-

+

|[[BRST5:Metastases_to_the_breast|Metastases to the breast]]

|Disease

|

Line 740: Line 812:

|

−

|-|[[BRST5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]

+

|-

+

|[[BRST5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]

|Disease

|

Line 750: Line 823:

|

−

|-|[[BRST5:Cowden_syndrome|Cowden syndrome]]

+

|-

+

|[[BRST5:Cowden_syndrome|Cowden syndrome]]

|Disease

|

Line 760: Line 834:

|

−

|-|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]

+

|-

+

|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]

|Disease

|

Line 770: Line 845:

|

−

|-|[[BRST5:Li-Fraumeni_syndrome,_TP53-associated|Li-Fraumeni syndrome, TP53-associated]]

+

|-

+

|[[BRST5:Li-Fraumeni_syndrome,_TP53-associated|Li-Fraumeni syndrome, TP53-associated]]

|Disease

|

Line 780: Line 856:

|

−

|-|[[BRST5:Li-Fraumeni_syndrome,_CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]

+

|-

+

|[[BRST5:Li-Fraumeni_syndrome,_CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]

|Disease

|

Line 790: Line 867:

|

−

|-|[[BRST5:CDH1-associated_breast_cancer|CDH1-associated breast cancer]]

+

|-

+

|[[BRST5:CDH1-associated_breast_cancer|CDH1-associated breast cancer]]

|Disease

|

Line 800: Line 878:

|

−

|-|[[BRST5:PALB2-associated_cancers|PALB2-associated cancers]]

+

|-

+

|[[BRST5:PALB2-associated_cancers|PALB2-associated cancers]]

|Disease

|

Line 810: Line 889:

|

−

|-|[[BRST5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]]

+

|-

+

|[[BRST5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]]

|Disease

|

Line 820: Line 900:

|

−

|-|[[BRST5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]

+

|-

+

|[[BRST5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]

|Disease

|

Bailey.Glen

Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors

1,874

edits